The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
Official Title: Hepatic Artery Infusion Chemotherapy Plus Lenvatinib vs Hepatic Artery Infusion Chemotherapy Plus Sorafenib for Advanced Hepatocellular Carcinoma
Study ID: NCT03775395
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with lenvatinib combined with HAIC in patients with advanced hepatocellular carcinoma (HCC)
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Name: Ming Shi, MD
Affiliation: Sun Yat-sen University
Role: PRINCIPAL_INVESTIGATOR